Clearmind Enhances U.S. IP Presence with Publication of Three Patent Applications Covering LSD, Ketamine and Ibogaine Combinations
The covered applications address potential therapeutic uses across a range of indications, including mental health disorders, such as depression and PTSD as well as substance use disordersVancouver, Canada, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. NASDAQ:CMND (the “Company”), a cl…